Elevated serum or CSF levels of interleukin-6 (IL-6) and S100B, a marker of astroglial activation and blood-brain barrier (BBB) disruption, were observed in several cases of post-COVID myoclonus and ataxia [10-12]. This evidence concerns the gene S100B and Myoclonus.